The Efficacy of Melatonin in Sleep Problems of Hemodialysis and Peritoneal Dialysis Patients

The Efficacy of Melatonin in Sleep Problems of Hemodialysis and Peritoneal Dialysis Patients

Sponsors

Lead Sponsor: Meander Medical Center

Collaborator: Dutch Kidney Foundation

Source Meander Medical Center
Brief Summary

Sleep problems can lead to a bad quality of life and a raise of morbidity, also in dialysis patients. Sleep problems can be caused by a disturbance of circadian rhythms in our body. For a good regulation of these circadian rhythms a uniform external synchronisation is necessary. This is the synchronisation of the biological clock of our body by light and other influences. In case of a disturbance of the external synchronisation, due to for example naps during the day or wake periods at night, internal rhythms can be unlinked. As a result a weakened melatonin rhythm and a problematic sleep-wake cycle can be observed. Most dialysis patients have sleep problems. Their sleep latency is prolonged. They often take a nap during the day and their sleep efficiency is poor. There has only been one study on the melatonin rhythm of dialysis patients. The conclusion of this study was that the melatonin rhythm of dialysis patients is weakened and disturbed, probably caused by renal insufficiency. In this study no link was made between melatonin rhythm and the nature and severity of possible sleep problems. In different studies with non-dialysis patients and a disturbed melatonin rhythm, exogenous melatonin at the right time leads to a recovery of the normal rhythm and the normal biological clock and a better quality of life.

The aim is to research the endogenous melatonin rhythm and to improve sleep problems of hemodialysis patients with a placebo-controlled study with exogenous melatonin. Next to this a substudy is performed, in which the effect of the change of daytime to nocturnal in hospital hemodialysis on sleep and melatonin is researched.

Overall Status Completed
Start Date April 2005
Completion Date July 2007
Primary Completion Date July 2007
Phase Phase 3
Study Type Interventional
Primary Outcome
Measure Time Frame
Sleep onset latency < 15 minutes
sleep efficiency > 85%
Normalized melatonin rhythm. Dim Light Melatonin Onset (DLMO) 21:00-23:00 hour
Enrollment 40
Condition
Intervention

Intervention Type: Drug

Intervention Name: Melatonin

Description: Melatonin 3 mg once-daily

Eligibility

Criteria:

Inclusion Criteria:

- Stable Peritoneal dialysis

- Stable Hemodialysis

- Age 18-85 years

Exclusion Criteria:

- use of hypnotics, MAO inhibitors or neuroleptics

- Liver disease

- Participation in drug investigation < 1 months to start

- Former use of melatonin

- Severe neurological/psychiatric disease

- Allergic to melatonin or additives

Gender: All

Minimum Age: 18 Years

Maximum Age: 85 Years

Healthy Volunteers: No

Overall Official
Last Name Role Affiliation
Piet ter Wee, MD, PhD Study Chair VU University Medical Center
Location
Facility: Meander Medical Center
Location Countries

Netherlands

Verification Date

January 2008

Has Expanded Access No
Condition Browse
Study Design Info

Allocation: Randomized

Intervention Model: Crossover Assignment

Primary Purpose: Treatment

Masking: Double

Source: ClinicalTrials.gov